19 October 2017
The Generic and Biosimilar Medicines Association (GBMA) Board today announces the resignation of CEO Belinda Wood.
Ms Wood is well known within the pharmaceutical and life sciences industry, having been with the association for the past five years, and its CEO since 2014. She was pivotal in the signing of, and subsequent extension to, the strategic agreement with Government. This helped position the GBMA as the premier association for biosimilars and generic medicines, delivering important generic price increases aimed at securing continuity of supply for Australian patients for everyday medicines. GBMA’s enhanced reputation with Government has enabled GBMA to have a ‘seat at the table’ for policy ongoing discussions.
“It has been an honour to lead GBMA as its CEO for the past 3 years. When I took the role, my focus was to deliver certainty for the generic and biosimilar medicines industry, to increase the use of affordable medicines and to secure a predictable market access pathway for biosimilars,” said GBMA CEO Belinda Wood.
“Having achieved those goals, and securing and extending the strategic agreement with Government, the time is right for me to look for the next opportunity knowing I leave the GBMA well placed for the future,” she said.
“Belinda has steered the GBMA through its most significant period of change. Her collaborative leadership and personal integrity has seen GMiA evolve into the GBMA we know today. The GBMA Board thanks her for her strong performance, her commitment to the GBMA and its members, and we wish her the very best in the future,” said GBMA Chair Allan Tillack.
GBMA will now look to recruit a new executive to lead the association through its next phase in implementing the key elements of the extended strategic agreement.
– ENDS –